IMM:ASX
Immutep Ltd
A$0.048
arrow_upward
+2.13%(+0.0010) 1D
Sep 4, 4:10:25 PM GMT+10 · AUD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IMM...
Open
A$0.05
High
A$0.05
Low
A$0.05
Mkt. cap
66.49M
Avg. vol.
5.50M
Volume
6.51M
52-wk high
A$0.47
52-wk low
A$0.03
EPS
-A$0.06
Shares outstanding
1.47B
No. of employees
19
Open
A$0.05
High
A$0.05
Low
A$0.05
Mkt. cap
66.49M
Avg. vol.
5.50M
Volume
6.51M
52-wk high
A$0.47
52-wk low
A$0.03
EPS
-A$0.06
Shares outstanding
1.47B
No. of employees
19
Profile
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
About Immutep Ltd